Hims & Hers Health, Inc. (HIMS) vs Immunovant, Inc. (IMVT)

A side-by-side comparison of Hims & Hers Health, Inc. and Immunovant, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — HIMS vs IMVT

growth of $100 · dividends reinvested · last 7y
HIMS +202.8% (+17.1%/yr)IMVT +235.2% (+18.9%/yr)IMVT compounded faster over this window
0200400600Start $100202120232025$303$335
HIMS IMVT

HIMS vs IMVT: by the numbers

  • •HIMS is the larger company ($6.52B vs $6.49B market cap).
  • •Both run net losses; HIMS's is the smaller (-5.51% vs -7585.86% net margin).

Metrics side by side

Valuation

MetricHIMSIMVT
P/S ratio2.53914.74
P/B ratio20.118.83
FCF yield1.38%N/A

Profitability

MetricHIMSIMVT
Gross margin73.84%0.00%
Operating margin4.50%0.00%
Net margin-5.51%-7585.86%
ROE-43.83%-73.19%
ROIC-4.30%-76.00%

Growth (annualized)

MetricHIMSIMVT
Revenue CAGR (5Y)67.47%N/A
Total return CAGR (5Y)32.23%29.93%

Frequently asked

How have HIMS and IMVT total returns compared?
Over the past 5 years, HIMS delivered 32.23% and IMVT delivered 29.93% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.